Development and Validation of the PREMMplus Model for Multigene Hereditary Cancer Risk Assessment.
Matthew B YurgelunHajime UnoC Sloane FurnissChinedu UkaegbuMiki HoriguchiAmal YussufHolly LaDucaAnu ChittendenJudy E GarberSapna SyngalPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
PREMMplus accurately identifies individuals with PGVs in a diverse spectrum of cancer susceptibility genes with high sensitivity/NPV. Individuals with PREMMplus scores ≥ 2.5% should be considered for MGPT.